RATIONALE: Studying biopsy, bone marrow, and blood samples from patients with cytopenia that did not respond to treatment may help doctors learn more about the disease and plan the best treatment.
PURPOSE: This laboratory study is assessing immune function in young patients with cytopenia that did not respond to treatment.
Who can participate
Age range
17 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Diagnosis of refractory cytopenia (RC) including any of the following:
* Severe aplastic anemia (SAA)
* Fanconi's anemia
* Shwachman Diamond syndrome
* Dyskeratosis congenita
* Pearson syndrome
* All RC patients included in the EWOG MDS 2006 protocol irrespective of therapy
* Patients who have undergone hematopoietic stem cell transplantation (HSCT) may be enrolled on EWOG-MDS SCT RC RIC 06 or EWOG-MDS SCT MDS 06 protocol
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* No prior immunosuppressive therapy for refractory cytopenia
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study looked at immune function markers like TCR V beta oligoclonality and GPI-deficient clones in kids with conditions like Fanconi anemia or myelodysplastic syndromes — has my child already had any of these immune tests done, and what did the results show?
2Since this trial is completed, would it be worth asking whether the findings from this research changed how doctors now evaluate treatment-resistant cytopenia in children with my child's specific diagnosis?
3The study enrolled patients with cytopenia that didn't respond to treatment — does my child's situation match that profile, and if so, how would understanding their immune cell patterns actually change what treatment options we'd consider next?
4One thing this trial measured was abnormal T-cell populations (oligoclonal T-cell expansion) — can you explain whether this type of immune abnormality is something my child's care team is actively monitoring for, and what it would mean if they found it?
5Since this study covered several different rare conditions including Shwachman-Diamond syndrome and Pearson syndrome alongside more common ones like MDS, does the immune function picture look different depending on which diagnosis a child has, and how does that apply to my child's case?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of patients with TCR V beta oligoclonality at diagnosis
Timeframe: 96 months
2
Immunophenotype of patients with oligoclonal T-cell expansion
Timeframe: 96 months
3
Number of patients with glycophosphatidylinositol (GPI) deficient clones